BCRX NASDAQ
BioCryst Pharmaceuticals, Inc.
1W: +2.0%
1M: -4.4%
3M: -15.0%
YTD: +8.0%
1Y: +12.5%
3Y: +37.8%
5Y: -46.1%
$8.10
+0.22 (+2.79%)
Weekly Expected Move ±5.3%
$7
$7
$8
$8
$8
Credit Risk of going bust: lower than 54% of companies Debt: 16.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.15 (down 98%), BioCryst Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $409.9M against a stock market value of $2.07B.
Distance to default 5.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $197.7M (short-term plus half of long-term), stock volatility 47.5%; Altman Z'' -13.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.15 (down 98%), BioCryst Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $409.9M against a stock market value of $2.07B.
Distance to default 5.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $197.7M (short-term plus half of long-term), stock volatility 47.5%; Altman Z'' -13.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2025-06-30
Earliest Filing
2026-01-23
Latest Filing
target: 2
acquirer: 1
Counterparties (Filed by BCRX)
3 relationshipsCompanies named in BCRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Astria Therapeutics, Inc. | — | target | Target company in the merger with BioCryst Pharmaceuticals, Inc. | 2026-01-23 | View |
| Astria Therapeutics, Inc. | — | target | Target company in the merger agreement with BioCryst Pharmaceuticals, Inc. | 2025-10-14 | View |
| Neopharmed Gentili S.p.A. | — | acquirer | Purchased 100% of BioCryst Ireland Limited for $250 million in cash plus potential milestone payments. | 2025-06-30 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-08-04 | Exit/Disposal Costs | View | |
| 2026-06-29 | Exit/Disposal Costs; Regulation FD; Exhibits | View | |
| 2026-06-12 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-06 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-05-04 | Regulation FD; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-23 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Creati | Agreement Acquisition | View |
| 2026-01-23 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2026-01-09 | Regulation FD Disclosure | View | |
| 2025-12-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-11 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-14 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Departure/E | Agreement | View |
| 2025-10-01 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-08-11 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-31 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR